Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase
- 16 February 1996
- journal article
- research article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism
- Vol. 1299 (3), 353-357
- https://doi.org/10.1016/0005-2760(95)00226-x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- PAF-Degrading Acetylhydrolase Is Preferentially Associated With Dense LDL and VHDL-1 in Human PlasmaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Anti-inflammatory properties of a platelet-activating factor acetylhydrolaseNature, 1995
- Platelet-activating factor (PAF): Implications for coronary heart and vascular diseasesProstaglandins, Leukotrienes & Essential Fatty Acids, 1994
- Platelet‐activating factor acetylhydrolase activity in human tissues and blood cellsLipids, 1991
- Expression of elastase activity by human monocyte-macrophages is modulated by cellular cholesterol content, inflammatory mediators, and phorbol myristate acetate.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
- Biosynthesis of paf-acether XIV. Paf-acether output in murine peritoneal macrophages is regulated by the level of acetylhydrolaseBiochemical and Biophysical Research Communications, 1989
- Preformed PAF‐acether and lyso PAF‐acether are bound to blood lipoproteinsFEBS Letters, 1988
- CV-3988 - A specific antagonist of platelet activating factor (PAF)Life Sciences, 1983
- Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF)Clinical Immunology and Immunopathology, 1980
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959